CDK 4/6

Graphic image of two hands shaking with employeesexecutives on the forearms of each shaking hand

Biotech

Genentech pays $850M upfront for Regor's CDK inhibitors

Genentech is taking ownership of a breast cancer candidate that has shown signs of single-agent efficacy in patients failed by existing options.

Nick Paul Taylor Sep 30, 2024 5:30am

increase growth

Onconova files to raise dose cap in solid tumor trial

Mar 18, 2022 9:00am